Biological profiling of prospective antidepressant response in major depressive disorder: Associations with (neuro)inflammation, fatty acid metabolism, and amygdala-reactivity

Psychoneuroendocrinology

Volumn 79, Issue , 2017, Pages 84-92

  Mocking, R J T ^a   Nap, T S ^a   Westerink, A M ^a   Assies, J ^a   Vaz, F M ^b   Koeter, M W J ^a   Ruhe H G ^a,c   Schene, A H ^a,d,e  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e RADBOUD UNIVERSITY   (Netherlands)

Author keywords

Amygdala; Antidepressant; Arachidonic acid; CRP; Fatty acids; Longitudinal; Major depressive disorder; Neuroinflammation; Paroxetine; Response

Indexed keywords

ARACHIDONIC ACID; C REACTIVE PROTEIN; PAROXETINE; PLACEBO; ANTIDEPRESSANT AGENT; FATTY ACID;

ADULT; AGED; ALCOHOL CONSUMPTION; AMYGDALA; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; FAT INTAKE; FATTY ACID METABOLISM; FEMALE; FOOD DRUG INTERACTION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NERVOUS SYSTEM INFLAMMATION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; DIAGNOSTIC IMAGING; DRUG EFFECTS; INFLAMMATION; LIPID METABOLISM; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING;

ADULT; AMYGDALA; ANTIDEPRESSIVE AGENTS; C-REACTIVE PROTEIN; DEPRESSIVE DISORDER, MAJOR; FATTY ACIDS; FEMALE; HUMANS; INFLAMMATION; LIPID METABOLISM; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PAROXETINE; PROSPECTIVE STUDIES;

EID: 85014393104     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2017.02.019     Document Type: Article

References (63)

1. Adams, P.B., Lawson, S., Sanigorski, A., Sinclair, A.J., Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 31:Suppl (1996), S157–S161.
2. Anders, S., Tanaka, M., Kinney, D.K., Depression as an evolutionary strategy for defense against infection. Brain Behav. Immun. 31 (2013), 9–22.
3. Assies, J., Pouwer, F., Lok, A., Mocking, R.J., Bockting, C.L., Visser, I., Abeling, N.G., Duran, M., Schene, A.H., Plasma and erythrocyte fatty acid patterns in patients with recurrent depression: a matched case-control study. PLoS One, 5, 2010, e10635.
4. Assies, J., Mocking, R.J., Lok, A., Ruhé, H.G., Pouwer, F., Schene, A.H., Effects of oxidative stress on fatty acid- and one-carbon-metabolism in psychiatric and cardiovascular disease comorbidity. Acta Psychiatr. Scand. 130 (2014), 163–180.
5. Assies, J., Mocking, R.J., Lok, A., Koeter, M.W., Bockting, C.L., Visser, I., Pouwer, F., Ruhe, H.G., Schene, A.H., Erythrocyte fatty acid profiles and plasma homocysteine, folate and vitamin B6 and B12 in recurrent depression: implications for co-morbidity with cardiovascular disease. Psychiatry Res. 229 (2015), 992–998.
6. Bazinet, R.P., Laye, S., Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat. Rev. Neurosci. 15 (2014), 771–785.
7. Beck, A.T., Ward, C.H., Mendelson, M., Mock, J., Erbaugh, J., An inventory for measuring depression. Arch. Gen. Psychiatry 4 (1961), 561–571.
8. Calder, P.C., n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am. J. Clin. Nutr. 83 (2006), 1505S–1519S.
9. Dahl, J., Ormstad, H., Aass, H.C., Malt, U.F., Bendz, L.T., Sandvik, L., Brundin, L., Andreassen, O.A., The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology 45 (2014), 77–86.
10. Dantzer, R., O'Connor, J.C., Freund, G.G., Johnson, R.W., Kelley, K.W., From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9 (2008), 46–56.
11. Dinan, T., Siggins, L., Scully, P., O'Brien, S., Ross, P., Stanton, C., Investigating the inflammatory phenotype of major depression: focus on cytokines and polyunsaturated fatty acids. J. Psychiatr. Res. 43 (2009), 471–476.
12. Dinan, T.G., Inflammatory markers in depression. Curr. Opin. Psychiatr. 22 (2009), 32–36.
13. Drevets, W.C., Neuroimaging abnormalities in the amygdala in mood disorders. Ann. N. Y. Acad. Sci. 985 (2003), 420–444.
14. Duivis, H.E., Vogelzangs, N., Kupper, N., de Jonge, P., Penninx, B.W., Differential association of somatic and cognitive symptoms of depression and anxiety with inflammation: findings from the Netherlands Study of Depression and Anxiety (NESDA). Psychoneuroendocrinology 38 (2013), 1573–1585.
15. Eller, T., Vasar, V., Shlik, J., Maron, E., Pro-inflammatory cytokines and treatment response to escitaloprsam in major depressive disorder. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 32 (2008), 445–450.
16. Faul, F., Erdfelder, E., Buchner, A., Lang, A.G., Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav. Res. Methods 41 (2009), 1149–1160.
17. Fiedorowicz, J.G., Hale, N., Spector, A.A., Coryell, W.H., Neuroticism but not omega-3 fatty acid levels correlate with early responsiveness to escitalopram. Ann. Clin. Psychiatry 22 (2010), 157–163.
18. First, M.B., Gibbon, M., Spitzer, R.L., Williams, J.B., User Guide for the Structured Clinical Interview for DSM-IV Axis-1 Disorders. 1996, American Psychiatric Association, Washington, DC.
19. Flock, M.R., Skulas-Ray, A.C., Harris, W.S., Gaugler, T.L., Fleming, J.A., Kris-Etherton, P.M., Effects of supplemental long-chain omega-3 fatty acids and erythrocyte membrane fatty acid content on circulating inflammatory markers in a randomized controlled trial of healthy adults. Prostaglandins Leukot. Essent. Fatty Acids (PLEFA) 91 (2014), 161–168.
20. Fu, C.H.Y., Steiner, H., Costafreda, S.G., Predictive neural biomarkers of clinical response in depression: a meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies. Neurobiol. Dis. 52 (2013), 75–83.
21. Hamilton, J.P., Etkin, A., Furman, D.J., Lemus, M.G., Johnson, R.F., Gotlib, I.H., Functional neuroimaging of major depressive disorder: a meta-Analysis and new integration of baseline activation and neural response data. Am. J. Psychiatry 169 (2012), 693–703.
22. Hamilton, M., A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960), 56–62.
23. Hannestad, J., DellaGioia, N., Bloch, M., The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 36 (2011), 2452–2459.
24. Howren, M.B., Lamkin, D.M., Suls, J., Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 71 (2009), 171–186.
25. Inagaki, T.K., Muscatell, K.A., Irwin, M.R., Cole, S.W., Eisenberger, N.I., Inflammation selectively enhances amygdala activity to socially threatening images. Neuroimage 59 (2012), 3222–3226.
26. Irwin, M.R., Miller, A.H., Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav. Immun. 21 (2007), 374–383.
27. Jentsch, M.C., Van Buel, E.M., Bosker, F.J., Gladkevich, A.V., Klein, H.C., Oude Voshaar, R.C., Ruhe, E.G., Eisel, U.L., Schoevers, R.A., Biomarker approaches in major depressive disorder evaluated in the context of current hypotheses. Biomark. Med. 9 (2015), 277–297.
28. Kato, M., Serretti, A., Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol. Psychiatry 15 (2010), 473–500.
29. Kiecolt-Glaser, J.K., Belury, M.A., Porter, K., Beversdorf, D.Q., Lemeshow, S., Glaser, R., Depressive symptoms, omega-6:omega-3 fatty acids, and inflammation in older adults. Psychosom. Med. 69 (2007), 217–224.
30. Kiecolt-Glaser, J.K., Belury, M.A., Andridge, R., Malarkey, W.B., Glaser, R., Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial. Brain. Behav. Immun. 25 (2011), 1725–1734.
31. Kiecolt-Glaser, J.K., Belury, M.A., Andridge, R., Malarkey, W.B., Hwang, B.S., Glaser, R., Omega-3 supplementation lowers inflammation in healthy middle-aged and older adults: a randomized controlled trial. Brain. Behav. Immun. 26 (2012), 988–995.
32. Kiecolt-Glaser, J.K., Derry, H.M., Fagundes, C.P., Inflammation: depression fans the flames and feasts on the heat. Am. J. Psychiatry 172 (2015), 1075–1091.
33. Lener, M.S., Iosifescu, D.V., In pursuit of neuroimaging biomarkers to guide treatment selection in major depressive disorder: a review of the literature. Ann. N. Y. Acad. Sci. 1344 (2015), 50–65.
34. Lin, P.Y., Huang, S.Y., Su, K.P., A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol. Psychiatry 68 (2010), 140–147.
35. Lotrich, F.E., Sears, B., McNamara, R.K., Elevated ratio of arachidonic acid to long-chain omega-3 fatty acids predicts depression development following interferon-alpha treatment: relationship with interleukin-6. Brain. Behav. Immun. 31 (2013), 48–53.
36. Maes, M., Smith, R., Christophe, A., Cosyns, P., Desnyder, R., Meltzer, H., Fatty acid composition in major depression: decreased n-3 fractions in cholesteryl esters and increased C20:4n-6/C20:5n-3 ratio in cholesteryl esters and phospholipids. J. Affect. Disord. 38 (1996), 35–46.
37. Maes, M., Major depression and activation of the inflammatory response system. Dantzer, R., Wollman, E.E., Yirmiya, R., (eds.) Cytokines, Stress, and Depression, 1999, Springer, US, Boston MA, 25–46.
38. Mazereeuw, G., Herrmann, N., Ma, D.W., Hillyer, L.M., Oh, P.I., Lanctot, K.L., Omega-3/omega-6 fatty acid ratios in different phospholipid classes and depressive symptoms in coronary artery disease patients. Brain. Behav. Immun. 53:March (2015), 54–58, 10.1016/j.bbi.2015.12.009.
39. Miller, A.H., Raison, C.L., The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat. Rev. Immunol. 16 (2016), 22–34.
40. Mocking, R.J., Assies, J., Lok, A., Ruhe, H.G., Koeter, M.W., Visser, I., Bockting, C.L., Schene, A.H., Statistical methodological issues in handling of fatty acid data: percentage or concentration, imputation and indices. Lipids 47 (2012), 541–547.
41. Mocking, R.J., Verburg, H.F., Westerink, A.M., Assies, J., Vaz, F.M., Koeter, M.W., Ruhe, H.G., Schene, A.H., Fatty acid metabolism and its longitudinal relationship with the hypothalamic-pituitary-adrenal axis in major depression: associations with prospective antidepressant response. Psychoneuroendocrinology 59 (2015), 1–13.
42. Mocking, R.J., Harmsen, I., Assies, J., Koeter, M.W., Ruhe, H.G., Schene, A.H., Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl. Psychiatry, 6, 2016, e756.
43. Muscatell, K.A., Eisenberger, N.I., Dutcher, J.M., Cole, S.W., Bower, J.E., Links between inflammation, amygdala reactivity, and social support in breast cancer survivors. Brain. Behav. Immun. 53 (2016), 34–38.
44. Nathan, P.J., Phan, K.L., Harmer, C.J., Mehta, M.A., Bullmore, E.T., Increasing pharmacological knowledge about human neurological and psychiatric disorders through functional neuroimaging and its application in drug discovery. Curr. Opin. Pharm. 14 (2014), 54–61.
45. Palmer, S.M., Crewther, S.G., Carey, L.M., A meta-analysis of changes in brain activity in clinical depression. Front. Hum. Neurosci., 8, 2015.
46. Raison, C.L., Rutherford, R.E., Woolwine, B.J., Shuo, C., Schettler, P., Drake, D.F., Haroon, E., Miller, A.H., A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70 (2013), 31–41.
47. Redlich, R., Stacey, D., Opel, N., Grotegerd, D., Dohm, K., Kugel, H., Heindel, W., Arolt, V., Baune, B.T., Dannlowski, U., Evidence of an IFN-gamma by early life stress interaction in the regulation of amygdala reactivity to emotional stimuli. Psychoneuroendocrinology 62 (2015), 166–173.
48. Reeves, G., C-reactive protein. Aust. Prescr. 30 (2007), 74–76.
49. Rosenbaum, P.R., Rubin, D.B., The central role of the propensity score in observational studies for causal effects. Biometrika 70 (1983), 41–55.
50. Ruhé, H.G., Booij, J., Weert, H.C., Reitsma, J.B., Franssen, E.J., Michel, M.C., Schene, A.H., Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology 34 (2009), 999–1010.
51. Ruhé, H.G., Booij, J., Veltman, D.J., Michel, M.C., Schene, A.H., Successful pharmacologic treatment of major depressive disorder attenuates amygdala activation to negative facial expressions: a functional magnetic resonance imaging study. J. Clin. Psychiatry 73 (2012), 451–459.
52. Ruhé, H.G., Khoenkhoen, S.J., Ottenhof, K.W., Koeter, M.W., Mocking, R.J., Schene, A.H., Longitudinal effects of the SSRI paroxetine on salivary cortisol in Major Depressive Disorder. Psychoneuroendocrinology 52 (2015), 261–271.
53. Sarris, J., Murphy, J., Mischoulon, D., Papakostas, G.I., Fava, M., Berk, M., Ng, C.H., Adjunctive nutraceuticals for depression: a systematic review and meta-Analyses. Am. J. Psychiatry 173 (2016), 575–587.
54. Schins, A., Crijns, H.J., Brummer, R.J., Wichers, M., Lousberg, R., Celis, S., Honig, A., Altered omega-3 polyunsaturated fatty acid status in depressed post-myocardial infarction patients. Acta Psychiatr. Scand. 115 (2007), 35–40.
55. Strawbridge, R., Arnone, D., Danese, A., Papadopoulos, A., Herane Vives, A., Cleare, A.J., Inflammation and clinical response to treatment in depression: a meta-analysis. Eur. Neuropsychopharmacol. 25 (2015), 1532–1543.
56. Thase, M.E., Using biomarkers to predict treatment response in major depressive disorder: evidence from past and present studies. Dialogues Clin. Neurosci. 16 (2014), 539–544.
57. Tiemeier, H., van Tuijl, H.R., Hofman, A., Kiliaan, A.J., Breteler, M.M., Plasma fatty acid composition and depression are associated in the elderly: the Rotterdam Study. Am. J. Clin. Nutr. 78 (2003), 40–46.
58. Tynan, R.J., Weidenhofer, J., Hinwood, M., Cairns, M.J., Day, T.A., Walker, F.R., A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain. Behav. Immun. 26 (2012), 469–479.
59. Uher, R., Tansey, K.E., Dew, T., Maier, W., Mors, O., Hauser, J., Dernovsek, M.Z., Henigsberg, N., Souery, D., Farmer, A., McGuffin, P., An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am. J. Psychiatry 171 (2014), 1278–1286.
60. Valkanova, V., Ebmeier, K.P., Allan, C.L., CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J. Affect. Disord. 150 (2013), 736–744.
61. Vijendra, S., Shivani, P., Robust Outlier Detection Technique in Data Mining: A Univariate Approach ArXiv. 2014.
62. Walker, F.R., A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression?. Neuropharmacology 67 (2013), 304–317.
63. Zunszain, P.A., Hepgul, N., Pariante, C.M., Inflammation and depression. Cowen, J.P., Sharp, T., Lau, F.J.Y., (eds.) Behavioral Neurobiology of Depression and Its Treatment., 2013, Springer Berlin Heidelberg, Berlin Heidelberg, 135–151.